ArticlePediatric transplantation2025
Case Report: Hematopoietic Stem Cell Transplantation to Treat Severe Acquired Aplastic Anemia in a Pediatric Kidney Transplant Recipient.
Article in Pediatric transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematopoietic stem cell transplantation (HSCT) in solid organ transplant recipients has been reported in adults. However, data on children are scarce. We report a case of an allogeneic HSCT in a 14-year-old girl to treat idiopathic very severe aplastic anemia (SAA). CASE PRESENTATION: The girl developed end-stage renal disease at the age of 4 years following Shiga toxin hemolytic-uremic syndrome. The cadaveric kidney was grafted at the age of 7 years. Three years later, the patient was successfully treated for active humoral graft rejection and continued with tacrolimus and antihypertensive treatment. At 10 years, an absence epilepsy manifested; therefore, lamotrigine and ethosuximide were added. After 7 years of having a kidney transplant, the patient developed very severe pancytopenia and was diagnosed with SAA. Parvovirus B19 and EBV infections were documented. At the age of 14 years, she received allogeneic hematopoietic stem cells from a matched unrelated CMV-seronegative donor. Neutrophils engrafted on Day +19 and full donor chimerism was achieved. An acute graft-versus-host disease grade II regressed after the escalation of immune suppression, which aggravated arterial hypertension and triggered CMV reactivation treated with glomerular filtration rate-adjusted ganciclovir. Antiviral therapy deteriorated renal graft function. A high-risk transplantation-associated thrombotic microangiopathy was diagnosed on Day +42 and treated with eculizumab. Despite adoptive therapy with CMV-specific cytotoxic T-lymphocytes (Day +62) the pericardial effusion developed and required surgical drainage. Nevertheless, CMV viremia and polyserositis gradually progressed to multiorgan failure. The patient died on Day +95 after HSCT.
conclusionsDespite reported favorable outcomes in children who received allogeneic HSCT after kidney transplantation, there is a lack of evidence on how to overcome numerous challenges in these ultrarare cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.